Bausch Health’s Slow Rebuild Faces New Scrutiny After Lombard Odier Cuts Its Stake Bausch Health’s valuation suggests potential, but the stake cut shows how far the company still has to go to earn back full investor confidence.
Why Bausch Health Companies Stock Rocketed 11% Higher Today Investors were obviously impressed with the company's latest acquisition.
Hedge Fund Billionaire Carl Icahn's Q3: The Activist Goes Defensive, Dumps A Disaster, And Loads Up On EchoStar Carl Icahn's hedge fund Q3 portfolio reshuffle: $9.14B, concentrated, contrarian. Walked away from Bausch Health, added EchoStar.
Carl Icahn's Biggest Bet Just Torched Half His Fortune Carl Icahn's empire, IEP, has collapsed 80% due to Hindenburg's short-selling attack. Icahn's net worth is down 75%.
Insiders Signal Caution: A Deep Dive into Recent Trading Trends and Market Implications Corporate insiders, often privy to the most granular details of their companies' health and future prospects, have been sending a clear signal to the market over the past 12-18 months: caution. A significant surge in insider selling, particularly pronounced in 2025, has overshadowed buying activity, pushing the U.S. market
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites.
Billionaire Investor Buys Google And This Gold Miner Stock John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF.
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via Phase 3 trials.
Oklo, Quantum Computing And Transocean Are Among Top 10 Mid Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio? Top mid-cap stocks gain, led by energy companies due to increased oil prices from Middle East conflict. Oklo, Bausch Health, Quantum Computing among top performers.
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90% Carl Icahn boosts holdings in Illumina and JetBlue, showing confidence in biotech and airlines. He also trims exposure to Southwest Gas Holdings.
Bausch Health Says Carl Icahn Has 34% Economic Interest In Its Outstanding Shares This disclosure comes days after the company announced a new “poison pill” plan to safeguard shareholders’ rights and prevent hostile takeovers.
